CNC: who owns it, and who’s predicted to buy next
Centene Corp · Health Care · on the Prior Moves forward board for 2026-09-30 at rank #58. Research, not investment advice.
Predicted to buy next quarter
3 tracked investors are included in the model-ranked expectations for CNC in 2026-09-30. This is a forecast about a later filing, not a confirmation that anyone has bought the security or a recommendation to do so.
- Lee Ainslie · Maverick
- Chuck Akre · Akre Capital
- Brad Gerstner · Altimeter
Strongest ranked investor signal: Daniel Loeb. No calibrated purchase probability is shown.
Currently disclosed holders
From the most recent 13F books we track, 1 investor discloses a position in CNC (weight = share of that investor’s US equity book). A 13F can be up to 45 days stale.
| Investor | Book weight |
|---|---|
| Larry Robbins · Glenview | 2.2% |
Mutual fund and ETF holders
436 US mutual funds and ETFs from 164 fund families reported a position in CNC for the quarter ending 2026-06-30. Against their own report a quarter earlier, 116 raised shares, 84 opened a new position, 159 cut and 14 sold out. Source: SEC Form N-PORT, which funds file about 60 days after quarter end. Share counts, not trades: a change can reflect fund inflows rather than a decision about CNC.
| Fund family | Funds | Share of fund-held shares |
|---|---|---|
| Vanguard Index Funds | 8 | 44.7% |
| Ishares Trust | 17 | 13.3% |
| Harris Associates Investment Trust | 2 | 7.8% |
| Select Sector Spdr Trust | 1 | 3.2% |
| Vanguard Institutional Index Funds | 2 | 2.7% |
| Victory Portfolios Ii | 3 | 2.5% |
| Aqr Funds | 15 | 2.3% |
| T. Rowe Price Mid-Cap Value Fund, Inc. | 1 | 2.2% |
The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.
See the full ranked board on top picks, how the PriorScore is built on how it works, the honest edge numbers on methodology, and the running accuracy on the prediction leaderboard. Forward quarter 2026-09-30, data as of 2026-10-16. Research, not investment advice, see the disclaimer.